Literature DB >> 14994286

Phenotypic variation and FMRP levels in fragile X.

Danuta Z Loesch1, Richard M Huggins, Randi J Hagerman.   

Abstract

Data on the relationships between cognitive and physical phenotypes, and a deficit of fragile X mental retardation 1 (FMR1) gene-specific protein product, FMRP, are presented and discussed in context with earlier findings. The previously unpublished results obtained, using standard procedures of regression and correlations, showed highly significant associations in males between FMRP levels and the Wechsler summary and subtest scores and in females between these levels and the full-scale intelligence quotient (FSIQ), verbal and performance IQ, and some Wechsler subtest scores. The published results based on data from 144 extended families with fragile X, recruited from Australia and the United States within a collaborative NIH-supported project, were obtained using robust modification of maximum likelihood in pedigrees. The results indicated that processing speed, short-term memory, and the ability to control attention, especially in the context of regulating goal-directed behavior, may be primarily affected by the FMRP depletion. The effect of this depletion on physical phenotype was also demonstrated, especially on body and head height and extensibility of finger joints. It is recommended that further studies should rely on more accurate measures of FMRP levels, and use of larger samples, to overcome extensive variability in the data. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14994286     DOI: 10.1002/mrdd.20006

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  122 in total

Review 1.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

4.  iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth.

Authors:  Matthew E Doers; Michael T Musser; Robert Nichol; Erich R Berndt; Mei Baker; Timothy M Gomez; Su-Chun Zhang; Leonard Abbeduto; Anita Bhattacharyya
Journal:  Stem Cells Dev       Date:  2014-04-30       Impact factor: 3.272

5.  Adaptive behavior in infants and toddlers with Down syndrome and fragile X syndrome.

Authors:  Elizabeth A Will; Kelly E Caravella; Laura J Hahn; Deborah J Fidler; Jane E Roberts
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2018-02-05       Impact factor: 3.568

6.  Fragile X screening: attitudes of genetic health professionals.

Authors:  Kruti Acharya; Lainie Friedman Ross
Journal:  Am J Med Genet A       Date:  2009-02-15       Impact factor: 2.802

7.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

8.  Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome.

Authors:  Hailan Hu; Yi Qin; Genrieta Bochorishvili; Yinghua Zhu; Linda van Aelst; J Julius Zhu
Journal:  J Neurosci       Date:  2008-07-30       Impact factor: 6.167

Review 9.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

10.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.